AC Immune SA (ACIU) has released an update.
AC Immune SA announced receiving a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, marking progress in the Phase 2b Re𝜏ain trial of its Alzheimer’s treatment, ACI-35.030. The payment was triggered by a swift prescreening rate for the trial, which aims to enroll around 500 pre-symptomatic Alzheimer’s patients and has already garnered a total of CHF 40 million in milestone payments. Highlighting the potential of its active immunotherapy candidate and robust financial position, AC Immune anticipates reaching transformative milestones within its three-year operational cash runway.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
